The American Medical Association is taking aggressive action to remove insurance barriers blocking patients from accessing weight-loss medications like Ozempic and Wegovy. At its annual meeting in Chicago, the AMA House of Delegates adopted sweeping new policies recognizing obesity as a chronic disease that requires long-term treatment, not a condition patients should struggle to afford.

Why Are Insurance Companies Restricting Access to These Medications?

Despite the proven effectiveness of GLP-1 receptor agonists (medications that mimic a naturally occurring hormone to regulate appetite and blood sugar), many patients face steep out-of-pocket costs and insurance denials. Insurance companies often impose "fail first" requirements, meaning patients must try and fail with cheaper treatments before gaining approval for GLP-1 drugs. Some insurers also set arbitrary weight-loss targets or body mass index (BMI) thresholds as conditions for coverage, even when a doctor believes the medication is medically necessary.

The problem is particularly acute for Medicare patients. Federal law currently excludes anti-obesity medications from Medicare Part D coverage, meaning seniors often cannot access these drugs through their prescription benefit plans.

What Specific Changes Is the AMA Pushing For?

The AMA's new policies target multiple barriers to access. The organization is calling for:

• Insurance Coverage Parity: Public and private insurers should cover obesity treatments, including GLP-1 medications, bariatric surgery, behavioral therapy, and dietary counseling with the same generosity they offer for type 2 diabetes and cardiovascular disease, without annual caps or lifetime limits.
• Elimination of Arbitrary Metrics: Insurance companies should stop denying coverage based on insurer-defined weight-loss targets or BMI thresholds that don't align with individualized medical decision-making between doctors and patients.
• Affordable Pricing: The AMA is pushing for legislation requiring public and private insurers to provide GLP-1 medications at affordable formulary pricing, reducing out-of-pocket costs for patients.
• Medicare Reform: The organization is advocating for federal legislation to permanently repeal the Medicare Part D exclusion of anti-obesity medications and requiring all state Medicaid programs to include FDA-approved anti-obesity drugs on their formularies.
• Manufacturer Accountability: The AMA is opposing preferential pricing strategies where pharmaceutical companies offer discounts exclusively to telehealth or online providers, arguing this practice undermines the established doctor-patient relationship.

The AMA also emphasized that treatment decisions should be made through shared decision-making between physicians and patients, free from payer-imposed treatment hierarchies or mandatory sequencing requirements.

How Should GLP-1 Medications Be Used as Part of Comprehensive Care?

The AMA stressed that GLP-1 medications should not be prescribed in isolation. The organization's policies encourage doctors to use these drugs in accordance with evidence-based clinical indications within comprehensive care plans that include behavioral and lifestyle interventions. Before prescribing, physicians should evaluate patients for body-image concerns, weight history, and eating disorders.

Additionally, the AMA is pushing for equitable access to clinician-led lifestyle intervention programs, particularly for underserved, rural, and historically marginalized populations. Importantly, the AMA stated that coverage of these medications should not be conditioned on participation in lifestyle programs, recognizing that some patients may lack access to such resources.

What Does This Mean for Patients Right Now?

These policy changes represent the AMA's formal position, but they don't immediately change insurance coverage. However, they signal a major shift in how the medical establishment views obesity treatment. By classifying obesity as a chronic disease requiring sustained, evidence-based treatment, the AMA is positioning GLP-1 medications alongside insulin for diabetes or statins for cholesterol, not as elective weight-loss aids.

"Obesity is a chronic disease that requires sustained, evidence-based treatment and comprehensive support. As new therapies emerge, patients should not face insurmountable financial barriers to clinically appropriate care," said AMA President Bobby Mukkamala, MD.

Bobby Mukkamala, MD, President of the American Medical Association

The AMA's advocacy could influence state legislators, federal policymakers, and insurance companies to reconsider their coverage policies. Some states and employers may adopt similar positions, potentially expanding access over time. However, patients currently struggling with insurance denials may need to work with their doctors to appeal coverage decisions or explore patient assistance programs offered by manufacturers.

Why Is This Fight Important Beyond Weight Loss?

The stakes extend beyond weight management. Recent research suggests GLP-1 medications may offer unexpected health benefits. A large study of over 110,000 women found that those taking GLP-1 drugs had approximately 30% lower odds of developing breast cancer compared with non-users. While researchers emphasize this is an observational finding and not yet proof of causation, it highlights why access to these medications matters for overall health outcomes, not just weight loss.

The researchers believe multiple biological mechanisms may explain the breast cancer risk reduction, including weight loss itself, reduced chronic inflammation, improved insulin resistance, and effects on pathways involved in cancer development. Clinical trials are now being planned to test whether GLP-1 medications could help prevent breast cancer in high-risk women.

The AMA's push for equitable access ensures that patients who could benefit from these medications, whether for weight management, diabetes control, or potentially cancer prevention, aren't denied care based on insurance company policies or inability to pay.